GEN Exclusives

More »

GEN News Highlights

Back to Item »

Boehringer Ingelheim’s Afatinib Extends PFS in EGFR Mutation-Positive NSCLC

Phase III trial evaluated afatinib vs. pemetrexed/cisplatin therapy against late-stage disease.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Growing Fears Over Rise in Zika Virus Infections

With the recent announcement from the World Health Organization that the Zika virus is “now spreading explosively,” are you concerned with Zika infection in your area?

More »